All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-09-25T15:26:31.000Z

European Commission approved JZP458 for the treatment of ALL and lymphoblastic lymphoma

By Sabina Ray
Sep 25, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

Bookmark this article

On September 21, 2023, it was announced that JZP458 received approval from the European Commission for use in a multi-agent chemotherapy treatment in adult and pediatric patients (≥1 month) with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL), who have developed silent inactivation or hypersensitivity to E.Coli derived asparaginase.

JZP458 is an Erwina-derived asparaginase that was developed with next-generation recombinant technology and has a safety profile consistent with other asparaginase therapies. The approval is based on data from JZP458-201 (NCT04145531), a phase II/III clinical trial investigating  JZP458 chemotherapeutic regimen in 228 patients with ALL or LBL with sensitivity or inactivated E.Coli-derived asparaginase.

  1. PR Newswire. Jazz Pharmaceuticals receives European Commission approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-receives-european-commission-approval-for-enrylaze-a-recombinant-erwinia-asparaginase-or-crisantaspase-for-the-treatment-of-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma-301935590.html. Published September 21, 2023. Accessed September 22, 2023.

More about...
Drug approvalsJZP458JZP458-201Relapsed/Refractory

Your opinion matters

HCPs, what is your preferred format for educational content on the ALL Hub?
1 vote - 81 days left ...

Related articles

Add bookmark

JZP458 in ALL/LBL: Post hoc analysis from AALL1931 trial

We summarize results of the post hoc analysis from the AALL1931 trial assessing the safety of JZP458 in children and adult patients with ALL/LBL, presented during the EHA 2024 Congress by...

Jul 30, 2024
Add bookmark

JZP458 in ALL/LBL: Post hoc analysis from AALL1931 trial

We summarize results of the post hoc analysis from the AALL1931 trial assessing the safety of JZP458 in children and adult patients with...

Jul 30, 2024
Add bookmark

U.S. FDA approves blinatumomab as consolidation for adult and pediatric patients with CD19+ B-ALL, irrespective of MRD status

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab for the treatment of aged ≥1 month who...

Jun 17, 2024
Add bookmark

U.S. FDA approves blinatumomab as consolidation for adult and pediatric patients with CD19+ B-ALL, irrespective of MRD status

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved...

Jun 17, 2024
Add bookmark

Blinatumomab receives FDA approval for MRD+ Philadelphia negative B-ALL

After being granted accelerated approval in March 2018, blinatumomab has now been granted full FDA approval. Blinatumomab is a bispecific T-cell engager for the treatment of...

Jun 23, 2023
Add bookmark

Blinatumomab receives FDA approval for MRD+ Philadelphia negative B-ALL

After being granted accelerated approval in March 2018, blinatumomab has now been granted full FDA approval. Blinatumomab is a...

Jun 23, 2023
Add bookmark

Brexucabtagene autoleucel approved by the FDA for use in adult ALL

On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be approved by the U.S. Food and Drug Administration (FDA)...

Oct 5, 2021
Add bookmark

Brexucabtagene autoleucel approved by the FDA for use in adult ALL

On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be...

Oct 5, 2021

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox